Corticosteroid responsive conditions

Drug Safety Update

 October 2017: Methylprednisolone injectable medicine containing lactose (Solu-Medrone 40mg) do not use in patient's with cows milk allergy

 August 2017: Corticosteroids: rare risk of central serious chorioretinopathy with local as well as systemic use.

 December 2016: Cobicistat, ritonavir and coadministration with a steroid: risk of systemic corticosteroid adverse effects

 September 2007: Corticosteroids: early psychiatric side-effects

FOR DETAILED INFORMATION ON SAFETY ISSUES WHEN PRESCRIBING CORTICOSTEROIDS, REFER TO THE BNF using the links below.

Important safety information

Adrenal suppression

During prolonged therapy with corticosteroids, particularly with systemic use, adrenal atrophy develops and can persist for years after stopping. Abrupt withdrawal after a prolonged period can lead to acute adrenal insufficiency (AI), hypotension, or death. To compensate for a diminished adrenocortical response caused by prolonged corticosteroid treatment, any significant intercurrent illness, trauma, or surgical procedure requires a temporary increase in corticosteroid dose, or if already stopped, a temporary reintroduction of corticosteroid treatment. Patients on long-term corticosteroid treatment should carry a steroid treatment card which gives guidance on minimising risk and provides details of prescriber, drug, dosage and duration of treatment.

Treatment Cessation in Adults

Abrupt withdrawal after a prolonged period can lead to acute adrenal insufficiency, hypotension or death. Withdrawal can also be associated with fever, myalgia, arthralgia, rhinitis, conjunctivitis, painful itchy skin nodules and weight loss.

The magnitude and speed of dose reduction in corticosteroid withdrawal should be determined on a case-by–case basis, taking into consideration the underlying condition that is being treated, and individual patient factors such as the likelihood of relapse and the duration of corticosteroid treatment. Gradual withdrawal of systemic corticosteroids should be considered in those whose disease is unlikely to relapse and have:

• received more than 40 mg prednisolone (or equivalent) daily for more than 1 week;
• received ≥ prednisolone 5 mg (or equivalent) daily for 3 weeks or longer across all routes of administration (oral, topical, inhaled, intranasal, intra-articular);
• been given repeat doses in the evening;
• recently received repeated courses (particularly if taken for longer than 3 weeks);
• taken a short course within 1 year of stopping long-term therapy;
• other possible causes of adrenal suppression including patients with an established or suspected diagnosis of primary AI (e.g. Addison's disease, congenital adrenal hyperplasia (CAH), bilateral adrenalectomy or adrenal haemorrhage) or patients with an established or suspected diagnosis of AI due to hypopituitarism due to hypothalamo-pituitary disease who are either on permanent glucocorticoid replacement or require glucocorticoid replacement during illness or stress such as a surgical procedure.

Systemic corticosteroids may be stopped abruptly in those whose disease is unlikely to relapse and who have received treatment for 3 weeks or less and who are not included in the patient groups described above.

During corticosteroid withdrawal the dose may be reduced rapidly down to physiological doses (equivalent to prednisolone 7.5 mg daily) and then reduced more slowly. Assessment of the disease may be needed during withdrawal to ensure that relapse does not occur.

 National guidelines and the latest steroid card can be downloaded here https://www.endocrinology.org/adrenal-crisis